|
1) Hastings MH, Maywood ES, O'Neil JS. Cellular circadian pacemaking and the role of cytosolic rhythms. Curr Biol. 2008; 18: R805-5
|
|
|
|
2) 岡村均, 深田吉孝, 編. 時計遺伝子の分子生物学. 東京: シュプリンガー・フェアラーク東京; 2004
|
|
|
|
|
|
3) Okamura H, Doi M, Fustin JM, et al. Mammalian circadian clock system: molecular mechanisms for pharmaceutical and medical sciences. Adv Drug Deliv Rev. 2010; 62: 876-84
|
|
|
|
|
|
4) Matsuo T, Yamaguchi S, Mitsui S, et al. Control mechanism of the circadian clock for timing of cell division. Science. 2003; 302: 255-9
|
|
|
|
|
|
5) Fu L, Pelicano H, Liu J, et al. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002; 111: 41-50
|
|
|
|
|
|
6) Turek FW, Joshu C, Kohsaka A et al. Obesity and metabolic syndrome in circadian Clock mutant mice. Science. 2005; 308: 1043-5
|
|
|
|
|
|
7) Marcheva B, Ramsey KM, Buhr ED, et al. Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature. 2010; 466: 627-31
|
|
|
|
|
|
8) Doi M, Takahashi Y, Komatsu R, et al. Salt-sensitive hypertension in circadian clock-deficient mice involves dysregulated adrenal Hsd3b6. Nature Medicine. 2010; 16, 67-74
|
|
|
|
|
|
9) Okamura H, Miyake S, Sumi Y, et al. Photic induction of mPer1 and mPer2 in Cry-deficient mice lacking a biological clock. Science. 1999; 286: 2531-4
|
|
|
|
|
|
10) Yagita K, Tamanini F, van der Horst GTJ, et al. Molecular mechanisms of the biological clock in cultured fibroblasts. Science. 2001; 292: 278-92
|
|
|
|
|
|
11) Okamura H, Clock genes in cell clocks: Roles, actions, and mysteries. J Biol Rhythms. 2004; 19: 388-99
|
|
|
|
|
|
12) Hashiramoto A, Yamane T, Tsumiyama K, et al. Mammalian clock gene Cryptochrome regulates arthritis via proinflammatory cytokine TNF-α. J Immunol. 2010; 184: 1560-5
|
|
|
|
|
|
13) Ishida A, Mutoh T, Ueyama T, et al. Light activates the adrenal gland: Timing of gene expression and glucocorticoid release. Cell Metab. 2005; 2: 297-307
|
|
|
|
|
|
14) Conn JW. Presidential Addresses. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955; 45: 3-17
|
|
|
|
|
|
15) Gordon RD, Laragh JH, Funder JW. Low renin hypertensive states: perspectives, unsolved problems, future research. Trends Endocrinol Metab. 2005; 16: 108-13
|
|
|
|
|
|
16) Eide IK, Torjesen PA, Drolsum A, et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004; 22: 2217-26
|
|
|
|
|